Romosozumab, Clinical Trials, and Real-world Care of Patients with Osteoporosis

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2020 Sep 21

PMID 32953774

Citations 7

Authors

E Michael Lewiecki

Affiliations

Soon will be listed here.

Citing Articles

Analysis and validation of biomarkers of immune cell-related genes in postmenopausal osteoporosis: An observational study.

Chen L, Zhao Y, Qiu J, Lin X Medicine (Baltimore). 2024; 103(19):e38042.

PMID: 38728482 PMC: 11081595. DOI: 10.1097/MD.0000000000038042.

Identification and validation of iron metabolism genes in osteoporosis.

Li Z, Xu J, Shi S, Weng Y, Guo B, Che L BMC Med Genomics. 2024; 17(1):5.

PMID: 38169377 PMC: 10762978. DOI: 10.1186/s12920-023-01779-2.

Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives.

Lim S, Bolster M Int J Womens Health. 2022; 14:1733-1747.

PMID: 36544862 PMC: 9762257. DOI: 10.2147/IJWH.S315184.

Reactivation of Bone Lining Cells are Attenuated Over Repeated Anti-sclerostin Antibody Administration.

Hong A, Yang J, Lee J, Suh J, Lee Y, Kim J Calcif Tissue Int. 2022; 111(5):495-505.

PMID: 35925416 DOI: 10.1007/s00223-022-01013-8.

[Glucocorticoid-induced osteoporosis-Focus treatment (part 2)].

Oelzner P, Eidner T, Pfeil A Z Rheumatol. 2022; 81(2):125-133.

PMID: 35006381 DOI: 10.1007/s00393-021-01128-7.

References

Adler R, Fuleihan G, Bauer D, Camacho P, Clarke B, Clines G . Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2015; 31(1):16-35. PMC: 4906542. DOI: 10.1002/jbmr.2708. View

Cummings S, Ferrari S, Eastell R, Gilchrist N, Jensen J, McClung M . Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2017; 33(2):190-198. DOI: 10.1002/jbmr.3337. View

McClung M, Grauer A, Boonen S, Bolognese M, Brown J, Diez-Perez A . Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370(5):412-20. DOI: 10.1056/NEJMoa1305224. View

Cummings S, Cosman F, Lewiecki E, Schousboe J, Bauer D, Black D . Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res. 2016; 32(1):3-10. DOI: 10.1002/jbmr.3039. View

Cipriani C, Pepe J, Minisola S, Lewiecki E . Adverse effects of media reports on the treatment of osteoporosis. J Endocrinol Invest. 2018; 41(12):1359-1364. DOI: 10.1007/s40618-018-0898-9. View

Ferrari S, Libanati C, Lin C, Brown J, Cosman F, Czerwinski E . Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. J Bone Miner Res. 2019; 34(6):1033-1040. PMC: 6852155. DOI: 10.1002/jbmr.3722. View

Langdahl B, Libanati C, Crittenden D, Bolognese M, Brown J, Daizadeh N . Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017; 390(10102):1585-1594. DOI: 10.1016/S0140-6736(17)31613-6. View

McClung M, Brown J, Diez-Perez A, Resch H, Caminis J, Meisner P . Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. J Bone Miner Res. 2018; 33(8):1397-1406. DOI: 10.1002/jbmr.3452. View

Bouxsein M, Eastell R, Lui L, Wu L, de Papp A, Grauer A . Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. J Bone Miner Res. 2019; 34(4):632-642. DOI: 10.1002/jbmr.3641. View

10.

Lewiecki E, Binkley N, Bilezikian J . Treated Osteoporosis Is Still Osteoporosis. J Bone Miner Res. 2019; 34(4):605-606. DOI: 10.1002/jbmr.3671. View

11.

Miller P, Bolognese M, Lewiecki E, McClung M, Ding B, Austin M . Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43(2):222-229. DOI: 10.1016/j.bone.2008.04.007. View

12.

Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E . The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018; 29(10):2335-2343. PMC: 6154045. DOI: 10.1007/s00198-018-4604-8. View

13.

Hadji P, Zanchetta J, Russo L, Recknor C, Saag K, McKiernan F . The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2011; 23(8):2141-50. DOI: 10.1007/s00198-011-1856-y. View

14.

Lewiecki E, Blicharski T, Goemaere S, Lippuner K, Meisner P, Miller P . A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018; 103(9):3183-3193. DOI: 10.1210/jc.2017-02163. View

15.

Cosman F, Crittenden D, Adachi J, Binkley N, Czerwinski E, Ferrari S . Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016; 375(16):1532-1543. DOI: 10.1056/NEJMoa1607948. View

16.

Johansson H, Siggeirsdottir K, Harvey N, Oden A, Gudnason V, McCloskey E . Imminent risk of fracture after fracture. Osteoporos Int. 2016; 28(3):775-780. PMC: 5338733. DOI: 10.1007/s00198-016-3868-0. View

17.

Cipriani C, Capriani C, Irani D, Bilezikian J . Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res. 2012; 27(12):2419-28. DOI: 10.1002/jbmr.1800. View

18.

Saag K, Shane E, Boonen S, Marin F, Donley D, Taylor K . Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357(20):2028-39. DOI: 10.1056/NEJMoa071408. View

19.

Cosman F, Nieves J, Dempster D . Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. J Bone Miner Res. 2016; 32(2):198-202. DOI: 10.1002/jbmr.3051. View

20.

Sambrook P, Chen J, Simpson J, March L . Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust. 2010; 193(3):154-6. DOI: 10.5694/j.1326-5377.2010.tb03835.x. View